1. Home
  2. MLYS vs CASH Comparison

MLYS vs CASH Comparison

Compare MLYS & CASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$30.46

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Pathward Financial Inc.

CASH

Pathward Financial Inc.

HOLD

Current Price

$99.08

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
CASH
Founded
2019
1954
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
2023
1996

Fundamental Metrics

Financial Performance
Metric
MLYS
CASH
Price
$30.46
$99.08
Analyst Decision
Strong Buy
Buy
Analyst Count
6
3
Target Price
$48.67
$96.33
AVG Volume (30 Days)
1.3M
179.6K
Earning Date
05-11-2026
04-22-2026
Dividend Yield
N/A
0.21%
EPS Growth
37.43
18.88
EPS
N/A
1.57
Revenue
N/A
$839,894,000.00
Revenue This Year
N/A
$7.56
Revenue Next Year
N/A
$6.02
P/E Ratio
N/A
$61.75
Revenue Growth
N/A
11.29
52 Week Low
$12.59
$65.93
52 Week High
$47.65
$97.14

Technical Indicators

Market Signals
Indicator
MLYS
CASH
Relative Strength Index (RSI) 65.40 75.02
Support Level $26.85 $87.19
Resistance Level $31.09 N/A
Average True Range (ATR) 1.92 1.96
MACD 0.64 0.73
Stochastic Oscillator 89.85 86.37

Price Performance

Historical Comparison
MLYS
CASH

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

Share on Social Networks: